eligibility_summary
Part 1—prostate adenocarcinoma (no neuroendocrine/small/signet), 1 prior ARAT (2nd <60 d bridge OK), ≤3 mCRPC lines, ≤1 taxane (2nd <60 d OK), BRCA/ATM only after PARPi, no anti‑PCa products. Part 2—anal SCC, melanoma, HNSCC, squamous NSCLC, SCLC, ≥1 prior systemic (PD‑1/L1 for HNSCC/melanoma), ≤2 chemo lines. All—metastatic progression, tissue available, adequate status/labs, contraception/no pregnancy, exclude serious medical/psychiatric, malignancy <2y, untreated CNS mets, prior B7‑H3, steroid CI, transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 open-label trial of vobramitamab duocarmazine (MGC018) vs standard AR-axis therapy in mCRPC (Part 1) and single-arm MGC018 in other solid tumors (Part 2). MGC018 is an antibody–drug conjugate (human IgG1) targeting B7-H3 (CD276), after binding B7-H3 on tumor cells it is internalized and, via a cleavable linker, releases a duocarmycin DNA-alkylating payload that induces minor-groove alkylation and cell death, the IgG1 backbone may add Fc-mediated cytotoxicity and a bystander effect. Comparator drugs: abiraterone (small-molecule CYP17A1 inhibitor reducing androgen synthesis) and enzalutamide (small-molecule androgen receptor inhibitor). Targets/pathways: B7-H3–expressing tumor cells across mCRPC and multiple solid tumors, androgen synthesis and AR signaling in prostate cancer.